Research Topics
Species | M R PranzatelliSummaryAffiliation: Southern Illinois University School of Medicine Country: USA Publications
|
Detail Information
Publications
B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytesM R Pranzatelli
Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL 62794 9658, USA
Neurology 62:1526-32. 2004..Conventional immunotherapies often do not prevent relapse or permanent sequelae...
CCR4 Agonists CCL22 and CCL17 are Elevated in Pediatric OMS Sera: Rapid and Selective Down-Regulation of CCL22 by ACTH or CorticosteroidsMichael R Pranzatelli
Neuroimmunology Research Laboratory, National Pediatric Myoclonus Center, Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL, 62794 9643, USA
J Clin Immunol 33:817-25. 2013..To study the role of Th2-attracting chemokines in opsoclonus-myoclonus syndrome (OMS), a serious neurological paraneoplastic disorder in need of better immunological understanding and therapy...
BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapyMichael R Pranzatelli
Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Laboratory, and Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA
J Neuroinflammation 10:10. 2013..B-cell dysregulation has been implicated but not fully characterized in pediatric opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder...- Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disordersMichael R Pranzatelli
National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, Department of Neurology, Southern Illinois University School of Medicine, USA
J Neurol Sci 326:53-8. 2013..To test for hypothesized disease- and treatment-induced changes in cytokines and adhesion molecules in children with opsoclonus-myoclonus syndrome (OMS)... - Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonusMichael R Pranzatelli
Southern Illinois University School of Medicine, Springfield, IL, USA
Pediatr Blood Cancer 58:988-91. 2012..No further relapses have occurred in 3 years, but he remains on low-dose ACTH with neuropsychiatric residuals of OMS... - Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMSMichael R Pranzatelli
National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA
J Neuroimmunol 243:81-8. 2012..These data implicate the chemokine/chemoreceptor pair CXCL13/CXR5 in B cell recruitment to the CNS in OMS. CXCL13 and CXCL12 may serve as reciprocal biomarkers of disease activity, but CXCL13 also had utility as a treatment biomarker... - Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonusMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
J Clin Immunol 30:106-13. 2010..The study aim was to assess whether rituximab-induced B cell ablation in CSF outlasts repopulation in blood and if there are changes in other lymphocyte subsets... - B cell depletion therapy for new-onset opsoclonus-myoclonusMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
Mov Disord 25:238-42. 2010..Combination of rituximab with conventional agents as initial therapy was effective and safe. A controlled trial with long-term safety monitoring is indicated... - Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetilMichael R Pranzatelli
National Pediatric Myoclonus Center and Department of Neurology, SouthernIllinois University School of Medicine, Springfield, Illinois, USA
J Child Neurol 24:316-22. 2009..Mycophenolate mofetil did not prevent relapse. The novel effect of mycophenolate mofetil on chronically activated T cells may contribute to its efficacy in T-cell mediated neurological disorders... - Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndromeM R Pranzatelli
Department of Neurology, Division of Child and Adolescent Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
Neuropediatrics 39:164-71. 2008..These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids... - Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndromeMichael R Pranzatelli
National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Department of Neurology, Division of Child and Adolescent Neurology, 751 N Rutledge, Suite 3504, P O Box 19643, Springfield, IL 62794 9643, USA
Cytokine 44:26-32. 2008..The novel dose-related central and peripheral anti-BAFF properties of ACTH, especially, have implications for other BAFF-related autoimmune disorders, infectious diseases, and cancers... - Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndromeMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
J Pediatr Hematol Oncol 32:e167-72. 2010..They also suggest that pediatric rituximab dosing should be based on body weight, not surface area. (ClinicalTrials.gov NCT00244361)... - Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodoneMichael R Pranzatelli
National Pediatric Myoclonus Center, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
J Pediatr 147:372-8. 2005..Parents of children with opsoclonus-myoclonus syndrome (OMS) frequently describe poor sleep and rage attacks. We hypothesized that these manifestations are related and could result from underlying monoaminergic dysfunction... - Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndromeMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
J Pediatr Hematol Oncol 28:585-93. 2006..To determine if rituximab, an anti-CD20 monoclonal antibody, reduces cerebrospinal fluid (CSF) B-cell expansion in opsoclonus-myoclonus syndrome (OMS) and results in clinical improvement... - Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonusMichael R Pranzatelli
Division of Child and Adolescent Neurology, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
Pediatr Neurol 45:27-33. 2011..However, flow cytometry provides a more sensitive measure of B-cell infiltration. Cerebrospinal fluid oligoclonal bands warrant monitoring in long-term follow-up studies of disease-modifying drugs for opsoclonus-myoclonus... - Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMSMichael R Pranzatelli
National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Southern Illinois University School of Medicine, Springfield, IL 62794 9643, USA
Cytokine 53:384-9. 2011..These data reveal a major role for BAFF in peripheral B cell repopulation following rituximab-induced B-cell depletion, and novel changes in CXCL13. ClinicalTrials.gov NCT0024436... - Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonusMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois, USA
J Pediatr Hematol Oncol 26:718-23. 2004..To determine whether the distribution of peripheral blood mononuclear cells (PBMCs) is altered in paraneoplastic opsoclonus-myoclonus (POM)... - CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activityMichael R Pranzatelli
Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
Mov Disord 19:770-7. 2004..Immunophenotyping of CSF lymphocytes by flow cytometry yields valuable clinical information missed by routine studies and allows crucial treatment decisions to be made rapidly... - Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIGMichael R Pranzatelli
The National Pediatric Myoclonus Center, Departments of Neurology and Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
Mov Disord 17:1387-90. 2002..We report on an adult with opsoclonus-myoclonus-ataxia syndrome experiencing widely spaced neurological relapses, who was followed for 41 years. His responses to treatment are described... - Controlled pilot study of piracetam for pediatric opsoclonus-myoclonusM R Pranzatelli
National Pediatric Myoclonus Center, Department of Neurology, Southern Illinois University School of Medicine, PO Box 19658, Springfield, IL 62794-9658, USA
Clin Neuropharmacol 24:352-7. 2001..We found our rating scale to be a reliable and useful tool for future studies of opsoclonus-myoclonus in children... - Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndromeElizabeth D Tate
Southern Illinois University, School of Medicine, Division of Child and Adolescent Neurology, PO Box 19643, Springfield, IL 62794 9643, USA
J Pediatr Oncol Nurs 22:8-19. 2005..More than one half of the children had relapses. Residual behavioral, language, and cognitive problems occurred in the majority. The delay in diagnosis (11 weeks) and initiation of treatment (17 weeks) is unacceptably long... - Screening for autoantibodies in children with opsoclonus-myoclonus-ataxiaMichael R Pranzatelli
Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
Pediatr Neurol 27:384-7. 2002..They underscore the need to search for unique autoantibodies, as well as cellular mechanisms of pediatric paraneoplastic disease... - Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndromeMichael R Pranzatelli
Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
Pediatrics 115:e115-9. 2005..In addition to clarifying the immune response to B-cell depletion, these data reveal a promising new therapy for OMS that warrants a phase I clinical trial... - Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndromeM R Pranzatelli
Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory
Clin Exp Immunol 172:427-36. 2013..These data suggest alternative roles for CXCL10 in OMS. Over-expression of CXCL10 was not reduced by clinical immunotherapies as a whole, indicating the need for better therapeutic approaches... - Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterinMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, P.O. Box 19643, Springfield, IL 62702, USA
J Child Neurol 19:919-24. 2004.... - Chloral hydrate for progressive myoclonus epilepsy: a new look at an old drugM R Pranzatelli
The National Pediatric Myoclonus Center, Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, IL 62702, USA
Pediatr Neurol 25:385-9. 2001..Recent evidence of interactions with various excitatory and inhibitory amino acid neurotransmitter-operated ion channels as a mechanism of action may provide insight into altered neurotransmission in progressive myoclonus epilepsy... - Myoclonus in childhoodMichael R Pranzatelli
Department of Neurology, National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL 62702, USA
Semin Pediatr Neurol 10:41-51. 2003..Drug treatment is largely empiric but must be systematic and aimed at restoring activities of everyday living. Unlike in epilepsies, in myoclonus multiple drugs usually must be combined to attain functional improvement... - Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapyMichael R Pranzatelli
National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA
Pediatr Neurol 33:121-6. 2005..These data delineate differences in the central effects of ACTH and corticosteroid therapy, as well as between high and low ACTH doses, and support the integrity of the brain-adrenal axis in pediatric opsoclonus-myoclonus... - Infantile spasms versus myoclonus: is there a connection?Michael R Pranzatelli
Departments of Neurology and Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
Int Rev Neurobiol 49:285-314. 2002..Data can be collected easily through techniques such as back-averaging to resolve the issue of classification and localization of motor phenomena... - Neuroblastoma masquerading as benign childhood ataxia: an unrecognized medical emergencyMichael R Pranzatelli
J Emerg Med 26:242-3; author reply 243-4. 2004